Kornimate/medical-research-clean huggingface dataset:
5-hiaa in urine versus 5-hiaa in plasma patients with a serotonin producing neuroendocrine tumor'

Conditions: Neuroendocrine Tumors

Summary: the objective of this observational laboratory study is to measure the correlation between 5-hydroxyindolacetic acid (5-hiaa) in platelet rich plasma and 5-hiaa in 24-hours urine collection in adult patients with a serotonin-producing neuro-endocrine tumor. plasma and urine of included patients are collected and 5-hiaa values are measured with lcms-ms and analysed.

in midgut nets serotonin production is most prominent. patients with nets producing excessive serotonin can develop carcinoid syndrome. serotonin is a product of the 'tryptophan pathway'. serotonin is metabolized in 5-hydroxyindolacetic acid (5-hiaa) and then excreted with urine. 5-hiaa in 24-hour urine collection is one of the parameters used for follow up in patients with a serotonin-producing neuroendocrine tumor. this measurement has some disadvantages; it could be stressful, the collection is not always precisely, furthermore the collection could be problematic, for example in patients with diarrhea. since october 2013 it is possible, because of a better measurement sensitivity, to measure reliably 5-hiaa in platelet rich plasma (prp) by isotope-dilution massa-spectrometer (lcms-ms). recent publications show that 5-hiaa measured in prp could have an additive value in diagnosis and follow up of patients with serotonin-producing net. objective: the primary objective is to measure the correlation between 5-hiaa in prp and 5-hiaa in 24-hours urine collection in adult patients with a serotonin-producing neuro-endocrine tumor. secondary objective is to determine if increase or decrease of 5-hiaa in plasma is associated with disease progression. study design: this is an observational laboratory study. plasma and urine of included patients and collected in standard health care, are selected and the 5-hiaa's are measured with lcms-ms. also age, sex, diagnosis and clinical course of the patients will be collected from the medical record. study population: in this study the investigators will use blood and urine of 60 patients with serotonin-producing neuro-endocrine tumors. main study parameters/endpoints: the main endpoint of this study is the correlation between 5-hiaa in prp and 5-hiaa in 24-hour urine collection. secondary endpoint is the correlation between 5-hiaa in prp and course of the disease, determined by ct-scan (if applicable).

Eligibility criteria:
inclusion criteria: in order to be eligible to participate in this study, a subject must meet all of the following criteria: * serotonin in platelets \> 5.4 nmol / 10\^9 and 5-hiaa in 24-hours urine \>3.8 mmol/mol creatinine * adult net patients (aged ≥ 18 years of age) * blood and urine collection of the patient are collected within four days patients are allowed to be included more than once. exclusion criteria: * a potential subject who meets any of the following criteria will be excluded from participation in this study:

Keywords: neuroendocrine tumors 5-hydroxyindolacetic acid serotonin isotope-dilution massa-spectrometer
mobile phone personalized intervention for diabetes

Conditions: Diabetes Mellitus

Summary: with the development of economy and change of lifestyles, it is characterized that there is a dramatic increase of diabetes in china. changes in lifestyle/self-care behaviors by diabetes patients are required to improve blood glucose and subsequent outcomes. mobile phone intervention was a kind of high cost efficiency and high quality health care. our study evaluated a diabetes coaching system, using mobile phones and patient/provider portals for patient-specific treatment and communication.


Eligibility criteria:
inclusion criteria: 1. physician diagnosis of type 2 diabetes 2. age 20 years and more 3. the local resident exclusion criteria: 1. not currently managed by study physicians 2. pregnant 3. active substance, alcohol, or drug abuser 4. psychotic or schizophrenic under activecare 5. severe hearing or visual impairment 6. no telephone or mobile phone
efficacy of cognitive behavioral to hypnotherapeutic treatment of depression

Conditions: Major Depressive Disorder

Summary: the purpose of the study is to compare the efficacy of an hypnotherapeutic treatment of depression to cognitive behavioral treatment of depression in patients with mild to moderate major depressive episodes.

cognitive behavioral therapy (cbt) is considered to be an effective psychological treatment of mild to moderate major depressive episodes. effective treatments, however, show a reduction of depressive symptoms only up to 50 % (luty et al., 2007) which is one reason for the modification of the well-established cbt in the last years. following the 'third wave' approaches of cbt, e.g. emotion-focussed therapy or mindfulness-based cognitive therapy, techniques like meditation or the use of systemic or gestalt techniques within cbt has been applied. within this context, hypnotherapy-based strategies can also show an improvement of the current state of the art in depression psychotherapy. however, only few studies conducted randomised controlled trials to study the efficacy of hypnosis for depression as e.g. the comparison of cognitive hypnotherapy to cbt-alone (e.g. alladin and alibhai, 2007). with the present study, the efficacy of the hypnotherapeutic treatment of depression (hdt) will be compared to the cbt-based activation-focussed cognitive treatment of depression (acdt). both treatments are individually administered and includes 20 sessions. we expect hdt not being inferior to acdt in the reduction of depressive symptoms after six months of treatment.

Eligibility criteria:
inclusion criteria: * dsm-5 (diagnostic and statistical manual) criteria for current mild to moderate major depressive episode (mde) * informed consent * fluent in german * time for weekly therapy sessions * stable antidepressant medication since three months exclusion criteria: * a history of lifetime bipolar disorder, psychotic symptoms * a diagnosis of a chronic major depressive disorder (total duration of two years and more) * fulfilling the dsm-5 criteria for current severe mde or scores in madrs \>/= 35 or qidsc16 (quick inventory of depressive symptomatology) \>/= 16 * remission of current mde since more than four weeks prior to inclusion assessment * acute risk for suicide * severe cognitive impairment (confirmed suspicion with mini-mental-state-test \> 25) * a dominating primary diagnosis of another axis i disorder including anxiety disorders (e.g. panic disorder, posttraumatic stress disorder, anorexia nervosa, borderline personality disorder), or any severe substance-related abuse or dependence disorder * a physical illness which would interfere with regular psychotherapy sessions * outpatient psychotherapy during the last 12 months

Keywords: hypnotherapy; cognitive behavioral therapy; efficacy
a 6-month extension study to the b2061032 study to evaluate the safety, tolerability, and efficacy of dvs sr in the treatment of child and adolescent outpatients with mdd

Conditions: Major Depressive Disorder

Summary: this is a 6-month, open-label, flexible-dose study evaluating desvenlafaxine succinate sustained-release (dvs sr) in the treatment of child and adolescent outpatients with major depressive disorder (mdd).


Eligibility criteria:
inclusion criteria: * completed study b2061032 and who in the investigator's opinion, would benefit from long term treatment with dvs sr * willingness and ability to comply with scheduled visits, treatment plan, and procedures exclusion criteria: * requires precaution against suicide * not in generally healthy medical condition * poor compliance with study drug or study procedures during participation in study b2061032

Keywords: major depressive disorder mdd depression
rpe-p/tlif for lumbar spinal stenosis with instability

Conditions: Spinal Stenosis

Summary: objective to analyze the effectiveness and safety of robot-assisted percutaneous endoscopic posterior/transforaminal lumbar interbody fusion (rpe-p/tlif) in the treatment of lumbar spinal stenosis with instability. methods a single-center prospective study from september 2018 to april 2022, patients with lumbar spinal stenosis and instability who met the inclusion and exclusion criteria were treated with rpe-p/tlif. pain visual analog scale (vas) was used to evaluate the degree of low back pain and lower limb pain before operation, 1 month, 6 months, 1 year after operation and at the final follow-up, and the oswestry disability index (odi) was used to evaluate the degree of lumbar spinal function. at the last follow-up, macnab criteria were used to evaluate the clinical efficacy. imaging evaluation included the measurement of intervertebral space height, lumbar physiological curvature, fusion rate and pedicle screw accuracy by preoperative and lateral x-ray films.


Eligibility criteria:
inclusion criteria: patients who present with intermittent claudication accompanied by lower back pain, lumbar spine mri and/or ct findings of lumbar spinal stenosis, and x-ray images of over extension and over flexion indicating instability of the responsible segment of the lumbar spine, have severe symptoms that affect daily life and work, and have poor conservative treatment results. therefore, rpe-p/tlif single segment or double segment surgical treatment is recommended. exclusion criteria: (1) simple lumbar spinal stenosis without responsible segment instability; (2) long segment (3 or more) spinal stenosis with lumbar instability; (3) patients with major internal medicine underlying diseases who cannot tolerate surgery; (4) individuals with comorbid mental disorders or alzheimer's disease who are unable to cooperate with relevant scale filling and subsequent follow-up; (5) age\<18 years old.
anticholinergic deprescription in schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: in this study, the investigators will examine whether a deprescription of unnecessary anticholinergic drugs (benztropine or trihexyphenidyl) can augment quality of life, functioning, and neurocognition in individuals who with schizophrenia. individuals identified by clinical services who have unneeded prescriptions benztropine or trihexyphenidyl will be eligible for deprescription and study entry. following a baseline evaluation and magnetic resonance imaging (mri), participants will will be randomized to either staying on their anticholinergic drugs or undergoing deprescription per routine clinical care, and will undergo follow-up evaluations across 6 months. the investigators predict that reducing and deprescribing these drug, if clinically determined to be unnecessary will will enhance functioning, neurocognition


Eligibility criteria:
inclusion criteria: 1. primary dsm-defined diagnosis of schizophrenia or schizoaffective disorder verified by the structured clinical interview for dsm-5 (scid). 2. prescription of benztropine or trihexyphenidyl for at least 6 months 3. age 40-70 years. 4. acbs score \>= 3. 5. mild or absent extrapyramidal symptoms (determined by clinical pharmacists and prescribers). 6. competency and willingness to sign informed consent. inclusion criteria for the healthy control group: 1. age 40-70 years. 2. competency and willingness to sign informed consent. exclusion criteria: 1. serious anticholinergic side-effects (e.g., fever, blurred vision) indicative of a need for immediate removal of anticholinergics, 2. serious neurologic or medical condition/treatment that impacts the brain and neurodegenerative conditions such as parkinson's, dementia, etc.; autoimmune conditions such as multiple sclerosis (ms) and lupus; as well as traumatic brain injury (tbi). 3. significant risk of suicidal or homicidal behavior. 4. cognitive or language limitations, or any other factor that would preclude subjects providing informed consent. 5. contraindications for mr imaging (e.g., a pacemaker). 6. current scid-verified substance use disorder will be excluded to avoid the confounding impact of significant substance use comorbidity. participants with a history of substance use disorder that is in early or full remission will be eligible, to enhance generalizability. 7. patients concurrently treated with electroconvulsive therapy will be excluded because of its effects on cognition. exclusion criteria for healthy control (hc) subjects: 1. no history of psychotic illness and no active axis i disorder as determined by clinical interview using the scid-np. 2. score greater than 1 on the acb scale. 3. mr imaging contraindications. 4. neurologic conditions, any serious non-psychiatric disorder that could affect brain functioning, or intellectual disability. 5. hc with family history of psychosis will be excluded, as such individuals show subtle, but significant cognitive and neurobiological abnormalities. 6. individuals currently taking anticholinergic medications for reasons other than ssd.
the effect of synching prescription refills on adherence

Conditions: Hypertension; Hypercholesterolemia; Diabetes; Medication Adherence

Summary: to determine the effect of synchronizing a patient's prescription refill schedule on medication adherence. the targeted population is humana members who are currently taking 2 or more stars medications (hypertension, hypercholesterolemia, diabetes) and are current customers of rightsource. participants will be randomized to one of two groups. group one will be usual care and group two will be the rx synchronization group.


Eligibility criteria:
inclusion criteria: * humana members who are currently taking 2 or more stars medications (hypertension, hypercholesterolemia, diabetes) and are current customers of rightsource. exclusion criteria: * under 18 years of age
pilot study of safety and tolerability of nutrifriend cachexia in copd cachexia

Conditions: COPD; Cachexia

Summary: sf-k002 is a pilot study in patients with moderate to severe copd suffering from involuntary weight loss. the study is 12 weeks, double-blinded, placebo controlled and the main objective is to study the safety and tolerability of nutrifriend cachexia.

this study is a 12-week, randomised, parallel group, placebo controlled, multi-centre study. the primary objective is to evaluate the safety and tolerability of nutrifriend cachexia in patients with copd. the secondary objectives of the study are to evaluate effects on body composition, muscle function, daily activity, inflammation, lung function, compliance, appetite and quality of life.

Eligibility criteria:
inclusion criteria: * age \>50 years * moderate to severe copd patients with forced expiratory volume (fev1) of 30-60% * involuntary weight loss \<10% * 18 kg/m2 ≤ bmi ≤ 32 kg/m2 exclusion criteria: * exacerbation of copd within 3 months prior to screening * treatment with oral corticosteroids (\>5 mg/day) within 3 months prior to screening * treatment with anabolic steroids within 3 months prior to screening * current oxygen treatment or home ventilation therapy * change in smoking habits during the previous 6 months * major changes in copd maintenance treatment within 3 months prior to screening * other cachectic disorders such as cancer, renal or hepatic disorders
us-guided thoracic spinal epidural anesthesia vs ga for abdominal and breast surgeries

Conditions: Pain, Postoperative

Summary: ultrasound-guided combined thoracic segmental spinal epidural anesthesia in comparison with general anesthesia in upper abdominal and breast surgery.

the first group (s) will be given ultrasound-guided thoracic segmental spinal anesthesia at the level of t10 interlaminar space, patients will be in sitting position, a combined spinal epidural tray will be used. in this group, sonosite c60x/5-2 mhz m-turbo convex probe ultrasound transducer to identify the t10 interlaminar space and after complete sterilization, the investigator will introduce the epidural needle in a paramedian in plan approach till the epidural space. the spinal needle is then introduced through the epidural needle not more than 0.5 cm beyond the dura matter. 2cc of heavy marcaine plus 25 ug fentanyl are injected through the spinal needle. the epidural catheter is then threaded through the touhy needle after withdrawal of the spinal needle to keep only 4cm up in the epidural space.

Eligibility criteria:
inclusion criteria: * all upper abdominal and laparoscopic surgeries * asa i-iii class * age between 18 and 60 exclusion criteria: contraindication of regional asa more than iii age less than18 or more than 60 psychological troubles
nalmefene, baclofen and impulsivity in subjects with alcohol use disorder and healthy control subjects

Conditions: Alcohol Use Disorder

Summary: impulsivity is a central feature of addiction. nalmefen is an authorized treatment for alcohol addiction. baclofen has empathically been advocated to have some efficacy in this indication. the aim of the present study is to test the effect of nalmefene and baclofen on impulsivity. primary study objective: to examine the effect of nalmefene and baclofen on impulsivity (as measured by the stop signal task) in subjects with alcohol use disorder and healthy control subjects. main secondary study objectives: to examine the effect of nalmefene and baclofen on risk taking (as measured by the balloon analogue risk task) and on the preference for small immediate rewards over large delayed rewards (as measured by the delay discounting task). to compare subjects with alcohol use disorder and healthy control subjects on these tasks. primary study outcome: stop-signal reaction time in the stop-signal task main secondary study outcomes: equivalence point in the delay-discounting task and average number of pumps delivered in the balloon analogue risk task study design: randomized, placebo control, cross-over, single-dose


Eligibility criteria:
inclusion criteria: * 30 patients with dsm-5 diagnosis of alcohol use disorder, at least moderate (303.90/f10.20), * 30 sex and age-matched healthy controls, * over 18, informed consent. exclusion criteria: * opiate-treatment, * contra-indications for nalmefene and/or baclofen, * unstable psychiatric disorder, * pregnancy, * acute withdrawal syndrome.

Keywords: impulsivity nalmefene baclofen
68ga-dota-bombesin pet/mri in imaging patients with prostate cancer

Conditions: Prostate Carcinoma

Summary: this clinical trial studies the use of gallium-68 (68ga)-dota-bombesin as the imaging agent for positron emission tomography (pet)/magnetic resonance imaging (mri), collectively pet-mri, in patients with prostate cancer. pet uses a radioactive substance called 68ga-dota-bombesin, which attaches to tumor cells with specific receptors on their surfaces. the pet scanner takes pictures that capture where the radioactive drug is "lighting up" and attaching to tumor cells, which may help doctors recognize differences between tumor and healthy prostate tissue. mri uses radio waves and a magnet to make a picture of areas inside the body. using 68ga-dota-bombesin in diagnostic procedures, such as pet/mri, may allow doctors to identify smaller tumors than standard imaging.

primary objectives: i. to evaluate the feasibility and biodistribution of 68ga-dota-bombesin (bay 86-7548 or 68ga-dota rm2). outline: patients receive 68ga-dota-bombesin intravenously (iv) and then undergo pet/mri approximately 1 hour later. after completion of study, patients are followed up at 24 hours and 1 week.

Eligibility criteria:
inclusion criteria * provides written informed consent * known diagnosis of prostate cancer * patient has suspected recurrence based on biochemical data \[prostate-specific antigen (psa) \> 2 ng/ml\] * able to remain still for duration of each imaging procedure (about one hour) exclusion criteria * unable to provide informed consent * inability to lie still for the entire imaging time * inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) * any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance * metallic implants
evaluation of a hybrid prototype strategy (electrostimulation of lower limb muscles associated with voluntary strengthening of the upper limbs) in reconditioning to effort in patients with chronic paraplegia.

Conditions: Chronic Paraplegia

Summary: this single-centre study was carried out in collaboration with the cardiovascular research laboratory of harvard university (boston, usa). this preliminary study does not include a control group. the aim of this study was to investigate the effect of a hybrid reconditioning programme (electrostimulation of the lower limb muscles associated with voluntary strengthening of the upper limbs) on a specially developed rowing machine in patients presenting stabilized paraplegia of a traumatic origin. this study will bear on the increase in maximal aerobic capacity (vo2max) between the start and end of the 9-month reconditioning programme.


Eligibility criteria:
inclusion criteria: * male or female patients with paraplegia, ageb between 18 and 45 years * body mass index (bmi) between 18.5 and 29.9 * 2 to 15 years after the accident, asia a or b, lesion situated between t3 and t12 * medically stable * able to follow instructions * persons who have provided written informed consent exclusion criteria: * persons without national health insurance cover * arterial blood pressure \> 140/90 mmhg, arrythmia, heart disease, diabetes, impaired kidney function, cancer * smoking-induced intoxication, * medical treatment for cardiovascular disease or antidepressants * orthostatic hypotension with a symptomatic fall in arterial pressure \> 30 mmhg in the vertical position * grade 2 or more pressure sores * other associated neurological diseases (e.g. cerebrovascular accident, peripheral neuropathy, myopathy) * any disease affecting the shoulder that may compromise the ability to use the rowing machine. * coagulation disorders; * presence of an implanted electronic device * epilepsy